Provectus Biopharmaceuticals, Inc.

OTCPK:PVCT Stock Report

Market Cap: US$47.8m

Provectus Biopharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Provectus Biopharmaceuticals has been growing earnings at an average annual rate of 21.9%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 56.6% per year.

Key information

21.9%

Earnings growth rate

23.8%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate56.6%
Return on equityn/a
Net Margin-418.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Provectus Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:PVCT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241-310
30 Jun 241-310
31 Mar 241-310
31 Dec 231-310
30 Sep 231-310
30 Jun 231-310
31 Mar 231-320
31 Dec 221-420
30 Sep 221-420
30 Jun 221-420
31 Mar 220-520
31 Dec 210-620
30 Sep 210-621
30 Jun 210-621
31 Mar 210-722
31 Dec 200-723
30 Sep 200-723
30 Jun 200-723
31 Mar 200-724
31 Dec 190-724
30 Sep 190-834
30 Jun 190-734
31 Mar 190-734
31 Dec 180-835
30 Sep 180-945
30 Jun 180-1037
31 Mar 180-1238
31 Dec 170-1458
30 Sep 170-1788
30 Jun 170-23118
31 Mar 170-25138
31 Dec 160-29168
30 Sep 160-321611
30 Jun 160-291611
31 Mar 160-281511
31 Dec 150-251111
30 Sep 150-14109
30 Jun 150-12108
31 Mar 150-8106
31 Dec 140-10116
30 Sep 140-28104
30 Jun 140-28104
31 Mar 140-30104

Quality Earnings: PVCT is currently unprofitable.

Growing Profit Margin: PVCT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PVCT is unprofitable, but has reduced losses over the past 5 years at a rate of 21.9% per year.

Accelerating Growth: Unable to compare PVCT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PVCT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: PVCT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies